Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.91)
# 580
Out of 5,182 analysts
218
Total ratings
55.81%
Success rate
7.2%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $135 → $155 | $139.71 | +10.94% | 17 | Feb 11, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $985 → $1,205 | $935.58 | +28.80% | 15 | Feb 5, 2026 | |
| PFE Pfizer | Reiterates: Neutral | $27 | $28.32 | -4.66% | 17 | Feb 4, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $116 → $120 | $120.87 | -0.72% | 12 | Feb 4, 2026 | |
| AMGN Amgen | Maintains: Neutral | $315 → $350 | $347.94 | +0.59% | 19 | Feb 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $740 → $800 | $761.85 | +5.01% | 22 | Feb 2, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $105.43 | +6.23% | 2 | Oct 31, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $208.84 | +19.71% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $438.71 | +10.55% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $59.60 | -7.72% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $58.38 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $131.60 | +25.38% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $30.44 | -34.30% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $177.34 | +1.50% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $18.05 | +232.41% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.60 | +400.00% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.66 | +442.17% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $66.73 | +42.36% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $4.29 | +366.20% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $114.77 | -36.39% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.41 | +397.93% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.37 | +305.41% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $123.56 | +207.54% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $95.93 | -14.52% | 5 | Jan 16, 2019 |
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $135 → $155
Current: $139.71
Upside: +10.94%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $985 → $1,205
Current: $935.58
Upside: +28.80%
Pfizer
Feb 4, 2026
Reiterates: Neutral
Price Target: $27
Current: $28.32
Upside: -4.66%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $116 → $120
Current: $120.87
Upside: -0.72%
Amgen
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $350
Current: $347.94
Upside: +0.59%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $740 → $800
Current: $761.85
Upside: +5.01%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $105.43
Upside: +6.23%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $208.84
Upside: +19.71%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $438.71
Upside: +10.55%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $59.60
Upside: -7.72%
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $58.38
Upside: -
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $131.60
Upside: +25.38%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $30.44
Upside: -34.30%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $177.34
Upside: +1.50%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $18.05
Upside: +232.41%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.60
Upside: +400.00%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.66
Upside: +442.17%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $66.73
Upside: +42.36%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $4.29
Upside: +366.20%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $114.77
Upside: -36.39%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.41
Upside: +397.93%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.37
Upside: +305.41%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $123.56
Upside: +207.54%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $95.93
Upside: -14.52%